戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 en rendered obsolete by the recombinant OspA Lyme disease vaccine.
2  suggests that DbpA may not be suitable as a Lyme disease vaccine.
3 implicate DBP as a new candidate for a human Lyme disease vaccine.
4 n important consideration in the design of a Lyme disease vaccine.
5 e successfully developed a second-generation Lyme disease vaccine.
6 es a basis for rational design of OspA-based Lyme disease vaccines.
7 articipants enrolled in a phase III trial of Lyme disease vaccine; 118 participants had erythema migr
8 ken to examine the cost-effectiveness of the Lyme disease vaccine and the factors that influence its
9          This review outlines the history of Lyme disease vaccines and this movement to anti-tick vac
10 ol groups: 1) inflammatory arthritis but not Lyme disease vaccine (arthritis controls), 2) Lyme disea
11                                            A Lyme disease vaccine based on recombinant OspA has been
12                                  Recombinant Lyme disease vaccines based on purified preparations of
13                                            A Lyme disease vaccine, based on the Borrelia burgdorferi
14 yme disease vaccine (arthritis controls), 2) Lyme disease vaccine but not inflammatory arthritis (vac
15 ra from immune mice to identify new putative Lyme disease vaccine candidates.
16 m inflammatory arthritis had developed after Lyme disease vaccine (cases) were compared with 3 contro
17  effectiveness and cost-effectiveness of the Lyme disease vaccine in populations at various levels of
18 tor in determining the cost-effectiveness of Lyme disease vaccines in those areas.
19                                          The Lyme disease vaccine is based on the outer-surface lipop
20                                          The Lyme disease vaccine is cost-effective only for individu
21                   These results suggest that Lyme disease vaccine is not a major factor in the develo
22          The antigenic component of a common Lyme disease vaccine is recombinant outer surface protei
23 ified mRNA (mRNA-LNP) platform to generate a Lyme disease vaccine like the successful clinical vaccin
24 arthritis (vaccine controls), and 3) neither Lyme disease vaccine nor inflammatory arthritis (normal
25 r surface protein (Osp) A has been used as a Lyme disease vaccine that blocks transmission: OspA anti
26  highlighting use of BBI39 proteins as novel Lyme disease vaccines that can target pathogens in the h